文献リスト

1) Simpson SA, Tait JF, Wettstein A, et al. Isolierung eines neuen kristallisierten Hormons aus Nebennerien mit besonders hoher Wirksamkeit auf den Mineralsoffwechsel. Experientia. 1953; 9: 333-5

2) Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999; 341: 709-17

3) Pitt B, Remme W, Zannad F, et al; Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003; 348: 1309-21

4) Selye H. The general adaptation syndrome and the diseases of adaptation. J Clin Endocrinal Metab. 1946; 6: 117-230

5) Rocha R, Chander PN, Khanna K, et al. Mineralocorticoid blockade reduces vascular injury in stroke-prone hypertensive rats. Hypertension. 1998; 31: 451-8

6) Rocha R, Rudolph AE, Frierdich GE, et al. Aldosterone induces a vascular inflammatory phenotype in the rat heart. Am J Physiol Heart Circ Physiol. 2002; 283: H1802-10

7) de Kloet ER, Ruel JM, Sutanto W. Corticosteroids and the brain. J Steroid Biochem Mol Biol. 1990; 37: 387-94

8) Hollenberg SM, Weinberger C, Ong ES, et al. Primary structure and expression of a functional human glucocorticoid receptor cDNA. Nature. 1985; 318: 635-41

9) Arriza JL, Weinberger C, Cerelli G, et al. Cloning of human mineralocorticoid receptor complementary DNA: structural and functional kinship with the glucocorticoid receptor. Science. 1987; 237: 268-75

10) Bridgham JT, Carroll SM, Thornton JW. Evolution of hormone-receptor complexity by molecular exploitation. Science. 2006; 312: 97-101

11) Stewart PM, Corrie JE, Shackleton CH, et al. Syndrome of apparent mineralocorticoid excess. A defect in the cortisol-cortisone shuttle. J Clin Invest. 1988; 82: 340-9

12) Mune T, Rogerson FM, Nikkila H, et al. Human hypertension caused by mutations in the kidney isozyme of 11 beta-hydroxysteroid dehydrogenase. Nat Genet. 1995; 10: 394-9

13) Armanini D, Fiore C, Mattarello MJ, et al. History of the endocrine effects of licorice. Exp Clin Endocrinol Diabetes. 2002; 110: 257-61

14) Hatakeyama H, Miyamori I, Fujita T, et al. Vascular aldosterone. Biosynthesis and a link to angiotensin II-induced hypertrophy of vascular smooth muscle cells. J Biol Chem. 1994; 269: 24316-20

15) Takeda R, Hatakeyama H, Takeda Y, et al. Aldosterone biosynthesis and action in vascular cells. Steroids. 1995; 60: 120-4

16) Lombes M, Alfaidy N, Eugene E, et al. Prerequisite for cardiac aldosterone action. Mineralocorticoid receptor and 11 beta-hydroxysteroid dehydrogenase in the human heart. Circulation. 1995; 92: 175-82

17) Yoshida M, Ma J, Tomita T et al. Mineralocorticoid receptor is overexpressed in cardiomyocytes of patients with congestive heart failure. Congest Heart Fail. 2005; 11: 12-6

18) Kobayashi N, Yoshida K, Nakano S, et al. Cardioprotective mechanisms of eplerenone on cardiac performance and remodeling in failing rat hearts. Hypertension. 2006; 47: 671-9

19) Ohtani T, Ohta M, Yamamoto K, et al. Elevated cardiac tissue level of aldosterone and mineralocorticoid receptor in diastolic heart failure: Beneficial effects of mineralocorticoid receptor blocker. Am J Physiol Regul Integr Comp Physiol. 2007; 292: R946-54

20) 岩泰正. 血管平滑筋細胞におけるミネラロコルチコイド受容体の役割. 内分泌・糖尿病科. 2006; 23: 593-8

21) Takeda Y, Miyamori I, Yoneda T, et al. Synthesis of corticosterone in the vascular wall. Endocrinology. 1994; 135: 2283-6

22) Takeda Y, Miyamori I, Yoneda T, et al. Regulation of aldosterone synthase in human vascular endothelial cells by angiotensin II and adrenocorticotropin. J Clin Endocrinol Metab. 1996; 81: 2797-800

23) Kayes-Wandover KM, White PC. Steroidogenic enzyme gene expression in the human heart. J Clin Endocrinol Metab. 2000; 85: 2519-25

24) Yoshimura M, Nakamura S, Ito T, et al. Expression of aldosterone synthase gene in failing human heart: quantitative analysis using modified real-time polymerase chain reaction. J Clin Endocrinol Metab. 2002; 87: 3936-40

25) Gomez-Sanchez EP, Ahmad N, Romero DG, et al. Origin of aldosterone in the rat heart. Endocrinology 2004; 145: 4796-802

26) Xiao F, Puddefoot JR, Barker S, et al. Mechanism for aldosterone potentiation of angiotensin II-stimulated rat arterial smooth muscle cell proliferation. Hypertension. 2004; 44: 340-5

27) Silvestre JS, Robert V, Heymes C, et al. Myocardial production of aldosterone and corticosterone in the rat. J Biol Chem. 1998; 273: 4883-91

28) Ye P, Kenyon CJ, MacKenzie SM, et al. The aldosterone synthase (CYP11B2) and 11beta-hydroxylase (CYP11B1) genes are not expressed in the rat heart. Endocrinology. 2005; 146: 5287-93

29) Ahmad N, Romero DG, Gomez-Sanchez EP, et al. Do human vascular endothelial cells produce aldosterone？ Endocrinology. 2004; 145: 3626-9

30) Mazancovy K, Kopeck´y M, Miksik I, et al. 11beta-Hydroxysteroid dehydrogenase in the heart of normotensive and hypertensive rats. J Steroid Biochem Mol Biol. 2005; 94: 273-7

31) Nagata K, Obata K, Xu J, et al. Mineralocorticoid receptor antagonism attenuates cardiac hypertrophy and failure in low-aldosterone hypertensive rats. Hypertension. 2006; 47: 656-64

32) Qin W, Rudolph AE, Bond BR, et al. Transgenic model of aldosterone-driven cardiac hypertrophy and heart failure. Circ Res. 2003; 93: 69-76

33) Hatakeyama H, Inaba S, Miyamori I. 11beta-hydroxysteroid dehydrogenase in cultured human vascular cells. Possible role in the development of hypertension. Hypertension. 1999; 33: 1179-84

34) Hatakeyama H, Inaba S, Miyamori I. 11beta-hydroxysteroid dehydrogenase activity in human aortic smooth muscle cells. Hypertens Res. 2001; 24: 33-7

35) Cai TQ, Wong B, Mundt SS, et al. Induction of 11beta-hydroxysteroid dehydrogenase type 1 but not-2 in human aortic smooth muscle cells by inflammatory stimuli. J Steroid Biochem Mol Biol. 2001; 77: 117-22

36) Jaffe IZ, Mendelsohn ME. Angiotensin II and aldosterone regulate gene transcription via functional mineralocortocoid receptors in human coronary artery smooth muscle cells. Circ Res. 2005; 96: 643-50

37) Dover AR, Hadoke PW, Macdonald LJ, et al. Intravascular glucocorticoid metabolism during inflammation and injury in mice. Endocrinology. 2007; 148: 166-72

38) Kitagawa H, Yanagisawa J, Fuse H, et al. Ligand-selective potentiation of rat mineralocorticoid receptor activation function 1 by a CBP-containing histone acetyltransferase complex. Mol Cell Biol. 2002; 22: 3698-706

39) Yokota K, Shibata H, Kurihara I, et al. Coactivation of the N-terminal transactivation of mineralocorticoid receptor by Ubc9. J Biol Chem. 2007; 282: 1998-2010

40) Grossmann C, Krug AW, Freudinger R, et al. Aldosterone-induced EGFR expression: interaction between the human mineralocorticoid receptor and the human EGFR promoter. Am J Physiol Endocrinol Metab. 2007; 292: E1790 -800

41) Losel R, Feuring M, Wehling M. Non-genomic aldosterone action: from the cell membrane to human physiology. J Steroid Biochem Mol Biol. 2002; 83: 167-71

42) Mihailidou AS, Funder JW. Nongenomic effects of mineralocorticoid receptor activation in the cardiovascular system. Steroids. 2005; 70: 347 -51

43) Oliver WJ, Cohen EL, Neel JV. Blood pressure, sodium intake, and sodium related hormones in the Yanomamo Indians, a “no-salt"culture. Circulation. 1975; 52: 146-51

44) Robertson GL. The regulation of vasopressin function in health and disease. Recent Prog Horm Res. 1976; 33: 333-85

45) Gonick HC, Ding Y, Vaziri ND, et al. Simultaneous measurement of marinobufagenin, ouabain, and hypertension-associated protein in various disease states. Clin Exp Hypertens. 1998; 20: 617-27

46) Nishikawa T, Omura M. Clinical characteristics of primary aldosteronism: its prevalence and comparative studies on various causes of primary aldosteronism in Yokohama Rosai Hospital. Biomed Pharmacother. 2000; 54 Suppl 1: 83-5s

NPO医学中央雑誌刊行会 https://www.jamas.or.jp/ info@jamas.or.jp